AU2006213894B2 - Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses - Google Patents

Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses Download PDF

Info

Publication number
AU2006213894B2
AU2006213894B2 AU2006213894A AU2006213894A AU2006213894B2 AU 2006213894 B2 AU2006213894 B2 AU 2006213894B2 AU 2006213894 A AU2006213894 A AU 2006213894A AU 2006213894 A AU2006213894 A AU 2006213894A AU 2006213894 B2 AU2006213894 B2 AU 2006213894B2
Authority
AU
Australia
Prior art keywords
thiophene
biphenyl
amino
dimethyl
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006213894A
Other languages
English (en)
Other versions
AU2006213894A1 (en
Inventor
Mark Donald Chappell
Scott Eugene Conner
Allie Edward Tripp
Guoxin Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36694345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2006213894(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2006213894A1 publication Critical patent/AU2006213894A1/en
Application granted granted Critical
Publication of AU2006213894B2 publication Critical patent/AU2006213894B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2006213894A 2005-02-11 2006-02-09 Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses Ceased AU2006213894B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65249205P 2005-02-11 2005-02-11
US60/652,492 2005-02-11
PCT/US2006/004461 WO2006086488A2 (en) 2005-02-11 2006-02-09 Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses

Publications (2)

Publication Number Publication Date
AU2006213894A1 AU2006213894A1 (en) 2006-08-17
AU2006213894B2 true AU2006213894B2 (en) 2011-12-08

Family

ID=36694345

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006213894A Ceased AU2006213894B2 (en) 2005-02-11 2006-02-09 Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses

Country Status (25)

Country Link
US (1) US8084489B2 (enExample)
EP (1) EP1856090B1 (enExample)
JP (1) JP4988604B2 (enExample)
KR (1) KR20070104409A (enExample)
CN (1) CN101115735B (enExample)
AT (1) ATE445609T1 (enExample)
AU (1) AU2006213894B2 (enExample)
BR (1) BRPI0607015A2 (enExample)
CA (1) CA2597073C (enExample)
CR (1) CR9304A (enExample)
CY (1) CY1109624T1 (enExample)
DE (1) DE602006009773D1 (enExample)
DK (1) DK1856090T3 (enExample)
EA (1) EA200701705A1 (enExample)
ES (1) ES2332470T3 (enExample)
IL (1) IL184932A0 (enExample)
MA (1) MA29432B1 (enExample)
MX (1) MX2007009661A (enExample)
NO (1) NO20074567L (enExample)
PL (1) PL1856090T3 (enExample)
PT (1) PT1856090E (enExample)
SI (1) SI1856090T1 (enExample)
TN (1) TNSN07313A1 (enExample)
WO (1) WO2006086488A2 (enExample)
ZA (1) ZA200706354B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1758853E (pt) * 2004-06-14 2010-03-02 Lilly Co Eli Antagonistas do receptor de glucagon, sua preparação e usos terapêuticos
ES2494294T3 (es) 2007-02-09 2014-09-15 Metabasis Therapeutics, Inc. Antagonistas del receptor de glucagón
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2010019830A1 (en) 2008-08-13 2010-02-18 Metabasis Therapeutics, Inc. Glucagon antagonists
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
SG191040A1 (en) 2010-12-23 2013-08-30 Pfizer Glucagon receptor modulators
BR112013020035A2 (pt) 2011-02-08 2016-07-19 Pfizer moduladores do receptor do glucagon
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2734503B1 (en) 2011-07-22 2015-09-16 Pfizer Inc. Quinolinyl glucagon receptor modulators
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TW201427658A (zh) 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
WO2015066252A1 (en) 2013-11-04 2015-05-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions thereof, and methods of use
EP3154956A4 (en) 2014-06-12 2018-01-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
WO2017049140A2 (en) 2015-09-18 2017-03-23 Wake Forest University Health Sciences Angiotensin (1-7) analogs and methods relating thereto
WO2017059863A1 (en) 2015-10-05 2017-04-13 Hettwer Holding Aps Compositions and methods for treatment of bone defects
CA2914601A1 (en) * 2015-12-11 2017-06-11 Wake Forest University Health Sciences Angiotensin-(1-7) analogs and methods relating thereto
MX385598B (es) 2016-08-30 2025-03-18 Regeneron Pharma Anticuerpo inhibidor para usarse para tratar la resistencia severa a la insulina.
EP3529278A1 (en) 2016-10-20 2019-08-28 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
JP7781519B2 (ja) 2017-08-22 2025-12-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法
US12208071B2 (en) 2018-02-13 2025-01-28 Ligand Pharmaceuticals Incorporated Glucagon receptor antagonists
EP4285723A3 (en) 2019-12-20 2024-03-27 Bayer Aktiengesellschaft Substituted thiophene carboxamides, thiophene carboxylic acids and derivatives thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1463715A1 (en) * 2001-12-03 2004-10-06 Novo Nordisk A/S Novel glucagon antagonists
AU2003233780A1 (en) 2002-06-27 2004-01-19 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
EP1758859B1 (en) * 2004-05-28 2013-07-17 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
PT1758853E (pt) * 2004-06-14 2010-03-02 Lilly Co Eli Antagonistas do receptor de glucagon, sua preparação e usos terapêuticos

Also Published As

Publication number Publication date
EA200701705A1 (ru) 2008-02-28
PT1856090E (pt) 2009-11-18
WO2006086488A3 (en) 2006-12-14
DE602006009773D1 (de) 2009-11-26
ATE445609T1 (de) 2009-10-15
ZA200706354B (en) 2008-11-26
NO20074567L (no) 2007-11-08
US20100137417A1 (en) 2010-06-03
EP1856090A2 (en) 2007-11-21
EP1856090B1 (en) 2009-10-14
DK1856090T3 (da) 2009-11-30
CA2597073C (en) 2014-11-25
KR20070104409A (ko) 2007-10-25
AU2006213894A1 (en) 2006-08-17
BRPI0607015A2 (pt) 2009-12-01
TNSN07313A1 (en) 2008-12-31
MA29432B1 (fr) 2008-05-02
CN101115735B (zh) 2013-01-09
US8084489B2 (en) 2011-12-27
JP2008530102A (ja) 2008-08-07
CY1109624T1 (el) 2014-08-13
CA2597073A1 (en) 2006-08-17
IL184932A0 (en) 2007-12-03
ES2332470T3 (es) 2010-02-05
JP4988604B2 (ja) 2012-08-01
MX2007009661A (es) 2007-09-25
PL1856090T3 (pl) 2010-02-26
SI1856090T1 (sl) 2010-02-26
CR9304A (es) 2008-03-31
CN101115735A (zh) 2008-01-30
WO2006086488A2 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
AU2006213894B2 (en) Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses
AU2006342059B2 (en) Glucagon receptor antagonists, preparation and therapeutic uses
AU2010246329A1 (en) Glucagon receptor antagonists, preparation and therapeutic uses
AU2006342137B2 (en) Glucagon receptor antagonists, preparation and therapeutic uses
EP1758859B1 (en) Glucagon receptor antagonists, preparation and therapeutic uses
CA2629321C (en) Glucagon receptor antagonists, preparation and therapeutic uses
MX2008006699A (en) Glucagon receptor antagonists, preparation and therapeutic uses
EP1951659B1 (en) Glucagon receptor antagonists, preparation and therapeutic uses

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired